Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180527 | 0.88 | CYP4F2 (0.39) | ACACBFFAR1FFAR4PPARDPPARA | |
| SCHEMBL18180465 | 0.87 | FFAR1 (0.38) | ACACBFFAR1FFAR4PPARDPPARA | |
| SCHEMBL28747451 | 0.86 | VCP (0.46) | ACACBRAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL16367839 | 0.84 | ACACB (0.49) | ACACBRAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL9935172 | 0.84 | CA12 (0.50) | RAB9AMAPTALDH1A1NPC1TSHR | |
| SCHEMBL11544791 | 0.83 | ALDH1A1 (0.53) | ACACBALDH1A1NPC1L3MBTL1 | |
| SCHEMBL788820 | 0.83 | APP (0.49) | ACACBALDH1A1FFAR1FFAR4TSHR | |
| SCHEMBL852379 | 0.83 | L3MBTL1 (0.44) | RAB9AMAPTALDH1A1L3MBTL1CYP2A6 | |
| SCHEMBL2433672 | 0.83 | APP (0.45) | RAB9AMAPTALDH1A1NPC1FFAR1 | |
| SCHEMBL11236951 | 0.83 | LMNA (0.51) | RAB9AMAPTALDH1A1NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | ACACB 4567/4885RAB9A 1893/4885MAPT 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.